If your main goal is the highest average weight loss seen in large studies, GLP-1based medications lead the category, with semaglutide showing about 14.9% average loss at 68 weeks and tirzepatide showing up to about 20.9% at 72 weeks (dose-dependent)
Global obesity spending reached nearly $24bn in 2023, an over sevenfold growth in value in just three years, driven by the advent of new agents, and from 2024 onwards the market is forecasted to accelerate rapidly, with a possible 24-27% CAGR to 2028, and a potential value of up to $131bn by 2028, according to the IQVIA Institutes Global Use of Medicines 2024 report 4
Work with your doctor to find the best plan for you
8,9 Study population were insulin naive
Ali agreed that a proper diet is essential
Non-refundable once medication has been processed